Eisai acquires global rights to Belviq from Arena
WOODCLIFF LAKE, N.J. — Eisai Inc. has entered an agreement with Arena Pharmaceuticals Inc. to acquire all global development and marketing rights for Belviq and Belviq XR (lorcaserin hydrochloride), a chronic weight management treatment. Eisai said the agreement amends its November 2013 marketing and supply pact with Arena Pharmaceuticals GmbH. Under the deal announced this
